| oxaliplatin / Generic mfg. |
ChiCTR2100046238: Clinical study on adjuvant therapy of camrelizumab (SHR-1210) combined with SOX regimen in postoperative patients with cancer of gastroesophageal junction |
|
|
| Recruiting | 4 | 100 | | Camrelizumab + S1+ oxaliplatin | The Second Affiliated Hospital of Anhui Medical University; The Second Affiliated Hospital of Anhui Medical University, Jiangsu Hengrui Pharmaceutical Co., Ltd | gastric cancer | | | | |
2005-005085-36: Ihobiopsia neurotoksista sytostaattiadjuvanttihoitoon liittyvän Neuropatian diagnostiikassa |
|
|
| Ongoing | 4 | 60 | Europe | Intravenous infusion, Taxotere, Oncovin,Eloxatin | Anna-Liisa Kautio | cancer | | | | |
ChiCTR-TRC-10000961: Oxaliplatin combinating 5-fluorouracil and calcium folinic Acid Adjuvant chemotherapy after liver transplantation for hepatocellular carcinoma patients who do not meet Milan criteria |
|
|
| Completed | 4 | 60 | | Adjuvant chemotherapy after liver transplantation | General Hospital of Chinese People's Armed Police Force; Level of the institution：, General Hospital of Chinese People’s Armed Police Force | hepatocellular carcinoma (HCC) | | | | |
ChiCTR-TRC-09000345: Efficacy of transcatheter arterial chemoembolization with oxaliplatin combination regimen on hepatocellular carcinoma |
|
|
| Completed | 4 | 200 | | TACE with gemcitabine combined oxaliplatin regimen ;TACE with floxuridine combined oxaliplatin regimen | Department of interventional Radiology of Fujian Provincial Tumour Hospital; Level of the institution：, Self-funded | HCC | | | | |
ChiCTR-TNC-09000310: Adjuvant Chemotherapy Folfox Combined with Concurrent Radiotherapy in Postsurgery Gastric Cancer Patient: Phase I Trial |
|
|
| Completed | 4 | 24 | | Oxaliplatin 65 mg/m2 ;Oxaliplatin 85 mg/m2 ;Oxaliplatin 75 mg/m2 ;Oxaliplatin 75 mg/m2 | West China Hospital, Sichuan University; Level of the institution：, Self financed | Gastric Cancer | | | | |
ChiCTR-TRC-13003886: A Randomized, Controlled, Multicenter Clinical Trial of Kangai Injection in Combination with Chemotherapy XELOX in Treatment of Colorectal Cancer |
|
|
| Completed | 4 | 150 | | Kangai injection 60ml ivgtt D1-14 Q21d, combined with chemotherapy: Eloxatin 130mg/m2 2h ivgtt d1, Xeloda 1000mg/m2 bid po d1-14 Q21d ;Chemotherapy: Eloxatin 130mg/m2 2h ivgtt d1, Xeloda 1000mg/m2 bid po d1-14 Q21d | Guang'anmen Hospital affiliatied to China Academy of Chinese Medical Sciences; CHANGBAISHAN PHARMACEUTICAL CO., LTD, CHANGBAISHAN PHARMACEUTICAL CO., LTD | colorectal cancer | | | | |
ChiCTR-TNRC-11001557: A multi-center, non-randomized control clinical trail for Gemcitabine and Oxaliplatin combined with Sorafenib for HCC |
|
|
| Completed | 4 | 112 | | GEM 1000mg/m2 d1, I.V.ggt30-60/min ;Sorafenib 400mg bid po | Henan Cancer Hospital; Level of the institution：, Self financed | Liver cell cancer | | | | |
ChiCTR-TRC-09000477: A randomized control trial on the postoperative application of gemcitabine in patients with radical resection of biliary tract cancers |
|
|
| Completed | 4 | 90 | | Gemcitabine ;Gemcitabine+5-Fu ;Gemcitabine+Oxaliplatin | Sun Yet-sen Memorial Hospital of Sun Yet-sen University; Eli Lilly and Company, Eli Lilly and Company | Biliary tract cancer | | | | |
2005-000192-17: Gemcitabine and Oxaliplatin in the treatment of locally advanced or metastatic transitional cell carcinoma of the urinary tract in patients with impaired renal function and patients who have progressed on a cisplatin-based regimen |
|
|
| | 4 | 28 | Europe | Gemcitabine, Oxaliplatin, Gemzar, Eloxatin, Gemzar, Eloxatin | Barts & The London NHS Trust | Locally advanced or metastatic transitional cell carcinoma of the urinary tract | | | | |
2006-002832-10: Liitännäishoitona annetun oksaliplatiinipohjaisen solusalpaajahoidon jälkeinen hedelmällisyys kolorektaalisyöpäpotilailla. Pohjoismainen prospektiivinen tutkimus.Fertility in colorectal cancer patients after adjuvant oxaliplatin containing chemotherapy. A Nordic prospective study. |
|
|
| Ongoing | 4 | 10 | Europe | Intravenous infusion | Haukeland University Hospital | Kolorektaalisyöpä, colorectal cancer | | | | |
ChiCTR-OCH-13004042: Irinotecan plus oxaliplatin versus docetaxel plus oxaliplatin in advanced epithelial ovarian cancer |
|
|
| Completed | 4 | 200 | | CPT-11 plus oxaliplatin ;docetaxel plus oxaliplatin | Hebei Tumor Hospital; Hebei Tumor Hospital, self-financing | ovarian cancer | | | | |
2015-002202-37: Is concomitant administration of lidocaine during oxaliplatin infusion able to prevent acute nervepain as a result of oxaliplatin? Is het gelijktijdig toedienen van lidocaine gedurende oxaliplatin infusie in staat om zenuwpijn als gevolg van oxaliplatin te voorkomen |
|
|
| Ongoing | 4 | 24 | Europe | Lidocaine, RVG 51673, Infusion, Lidocaine Hydrochloride | radboudumc, Radboudumc | Acute oxaliplatin induced neuropathy Acute neuroapthie als gevolg van oxaliplatin, Acute oxaliplatin induced nerve pain Acute zenuwpijn als gevolg van oxaliplatin, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03] | | | | |
ChiCTR-IPR-16007912: Raltitrexed based transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a single-center randomized controlled study |
|
|
| Recruiting | 4 | 200 | | TACE (raltitrexed, epirubicin and oxaliplatin) ;TACE (epirubicin and oxaliplatin) | The First Affiliated Hospital, Sun Yat-sen University; The First Affiliated Hospital, Sun Yat-sen University, Patients and health care units、Study leader | Unresectable Hepatocellular Carcinoma | | | | |
RESOLVE study, ChiCTR-IPR-15006283: A Randomized, multicenter, controlled study to compare perioperative chemotherapy of Oxaliplatin combined with S-1(SOX) versus SOX or oxaliplatin with capecitabine(XELOX) as post-operative chemotherapy in locally advanced gastric adenocarcinoma with D2 dissection |
|
|
| Recruiting | 4 | 1059 | | Capecitabine: 1000 mg/m2, take two times a day, 1-14 days ;S-1: 40~60mg bid, 1-14 days ;S-1 single oral dose, S-1: 40-60mg bid, 1-14 days | Beijing Cancer Hospital; Beijing Cancer Hospital, Beijing Cancer Hospital | Gastric adenocarcinoma | | | | |
ChiCTR-IPR-15007047: Comparing the adjuvant chemotherapy regimens for advanced gastric cancer after laparoscopic D2 radical gastrectomy |
|
|
| Not yet recruiting | 4 | 100 | | Oxaliplatin 130mg/m2, iv drip d1; Capecitabine 1000mg/m2, Po, bid, d1-14, 21d/cycle, total of 8 cycles ;Oxaliplatin 130mg/m2, iv drip d1; S1 60mg, Po, bid, d1-14, 21d/cycle, total of 8 cycles. | Tianjin Medical University General Hospital; Tianjin Medical University General Hospital, Nil | gastric cancer | | | | |
ChiCTR-OPC-17010714: Apatinib Mesylate Tablets of joint mFOLFOX6 neoadjuant chemotherapy in locally advanced colorectal cancer clinical research |
|
|
| Recruiting | 4 | 60 | | Apatinib Mesylate Tablets of joint mFOLFOX6 neoadjuant chemotherapy | Tianjin people's hospital; Tianjin people's hospital, Jiang Su Heng Rui medicine. co.LTD | Colorectal cancer | | | | |
ChiCTR-OPC-16009563: DNA-repair defects and Platinum-based chemotherapy in metastatic castration-resistant prostate cancer |
|
|
| Recruiting | 4 | 17 | | Oxaliplatin plus pemetrexed | Huadong Hospital, Fudan University; Shanghai Shen Kang Medical Development Center, Clinical Research Plan of SHDC | prostate cancer | | | | |
ChiCTR-IPR-16010204: Prevention of recurrence after liver transplantation for hepatocellular carcinoma: comparison fo Iodine[131I] Metuximab Injection, Sorafenib, Chemotherapy and Iodine[131I] Metuximab Injection combined with Sorafenib. |
|
|
| Not yet recruiting | 4 | 120 | | oxaliplatin therapy ;Iodine[131I] Metuximab Injection therapy ;Sorafenib therapy ;Iodine[131I] Metuximab Injection combined with Sorafenib herapy | General Hospital of the Chinese People's Armed Police Forces; General Hospital of the Chinese people's armed police forces, Enterprise and Hospital | liver transplantation of HCC | | | | |
ChiCTR1800017323: A phase II study of apatinib combined with with XELOX regimen in the treatment of locally advanced gastric cancer |
|
|
| Recruiting | 4 | 20 | | apatinib combined with with XELOX regimen | The First Affliliated Hospital With Nangjing Medical University(Jiangsu Province Hospital); The First Affliliated Hospital With Nangjing Medical University(Jiangsu Province Hospital), Self financing | gastric cancer | | | | |
ChiCTR1800018546: A clinical study for Neoadjuvant Chemotherapy using apatinib plus L-OHP and capecitabine in local advanced gastric cancer |
|
|
| Not yet recruiting | 4 | 48 | | Apatinib combined with XELOX | The First Hospital of Lanzhou University; The First Hospital of Lanzhou University Intervention Department, Self raise independently | Locally advanced gastric cancer | | | | |
ChiCTR-OPC-17013602: Clinical study of apatinib combined with oxaliplatin in the treatment of platinum - resistant recurrent ovarian cancer . |
|
|
| Not yet recruiting | 4 | 20 | | Apatinib Tablets orally | Xin qiao Hospital, Chong qing; Xinqiao Hospital, Chong qing, self financing | Ovarian cancer | | | | |
ChiCTR1800018480: Clinical study of Oxaliplatin +5-FU intra-arterial infusion chemotherapy combined with doxorubicin-loaded microsphere embolization for gastric cardia cancer |
|
|
| Not yet recruiting | 4 | 50 | | Oxaliplatin +5-FU intra-arterial infusion chemotherapy combined with doxorubicin-loaded microsphere embolization | The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, self-financing | gastric cardia cancer | | | | |
ChiCTR1800015640: A study for Pegaspargase, Gemicitabine, Oxaliplatin and Dexamethasone (Peg-GemOD) Regimen followed by ASCT in the treatment of advanced-stage Extranodal NK/T cell lymphoma |
|
|
| Recruiting | 4 | 37 | | Pegaspargase, Gemicitabine, Oxaliplatin and Dexamethasone (Peg-GemOD) Regimen followed by ASCT | Shanghai Ninth People's Hospital Affiliated to Shanghai JiaoTong University School of Medcine; Shanghai Ninth People's Hospital Affiliated to Shanghai JiaoTong University School of Medcine, Project of Clinical Research， Shanghai Ninth People's Hospital Affiliated to Shanghai JiaoTong University School of Medcine | Nk/T cell lymphoma | | | | |
ChiCTR-OPC-17012564: Study of convernsion therapy using SOX chemotherapy plus Apatinib in local advanced or metastatic gastric cancer |
|
|
| Recruiting | 4 | 30 | | S-1+ oxaliplatin+aptinib | Zhejiang Province People's Hospital; Zhejiang Province People's Hospital, 1.Hengrui Company, Jiangsu, China，2.self-raised funds | Gastric cancer | | | | |
2020-003697-52: Systemic Neoadjuvant and adjuvant Control by Precision medicine in rectal cancer (SYNCOPE) – approach on high-risk group to reduce metastases Systeeminen syöpäkontrolli peräsuolisyövässä esi- ja liitännäishoidon sekä täsmähoidonvalinnan avulla – kaukoetäpesäkkeiden vähentäminen korkean riskin potilailla |
|
|
| Ongoing | 4 | 93 | Europe | Coated tablet, Concentrate for solution for infusion, Capesitabine Orion, Oxaliplatin Accord | Helsinki University Hospital | Rectal cancer, Rectal cancer, Diseases [C] - Cancer [C04] | | | | |
ChiCTR1800018854: A study for apatinib combined with biweekly oxaliplatin and S-1(SOX) as first-line therapy in patients with advanced stomach or gastro esophageal junction cancer |
|
|
| Recruiting | 4 | 242 | | Apatinib+SOX（biweekly） | The First Affiliated Hospital Zhejiang University; The first affiliated hospital Zhejiang University, self-financing | gastric cancer | | | | |
ChiCTR1800019212: A prospective, open-label clinical study for apatinib combined with mFOLFOX6 chemotherapy in the treatment of postoperative colorectal cancer |
|
|
| Not yet recruiting | 4 | 50 | | apatinib combined with mFOLFOX6 chemotherapy | The Second Affiliated Hospital of Chongqing Medical University; The Second Affiliated Hospital of Chongqing Medical University, Jiangsu hengrui pharmaceutical co. LTD | colorectal cancer | | | | |
ChiCTR1800016138: Effectiveness and safety of Apatinib combined SOX regimen for conversion therapy of unresectable advanced gastric cancer |
|
|
| Recruiting | 4 | 20 | | aptinib+S-1+ oxaliplatin | Yantai Yuhuangding Hospital; Yantai Yuhuangding Hospital, self-finacing | Gastric cancer | | | | |
ChiCTR2000028845: Anti-PD-1 Antibody Carrizumab combined with Apatinib and SOX versus Carrizumab combined with SOX versus SOX in transformation treatment of critical resectable gastric cancer: a randomized, single-center and controlled trial |
|
|
| Recruiting | 4 | 93 | | Carrilizumab, Aptinib, S-1 and Oxaliplatin ;Carrilizumab, S-1 and Oxalipla ;S-1 and Oxalipla | Shandong Provincial Hosptial; Shandong Provincial Hosptial, self-financing | Gatric cancer | | | | |
ChiCTR1800014478: Clinical study of apatinib combined with second - line chemotherapy for metastatic colorectal cancer |
|
|
| Not yet recruiting | 4 | 60 | | Apatinib + second-line chemotherapy regimen (standard regimen of 5-Fu in combination with irinotecan / oxaliplatin) ;second-line chemotherapy regimen (standard regimen of 5-Fu in combination with irinotecan / oxaliplatin) | Yibin Second People's Hospital; Yibin Second People's Hospital, Self financing | colorectal cancer | | | | |
ChiCTR2000040027: Prophylactic administration of recombinant human thrombopoietin in the secondary prevention of thrombocytopenia induced by XELOX adjuvant chemotherapy in patients with stage III colorectal cancer |
|
|
| Recruiting | 4 | 30 | | Preventive use of recombinant human thrombopoietin | Ordos Central Hospital, Inner Mongolia; Ordos Central Hospital, Innovation and Entrepreneurship Project of Ordos Health Commission、Independent scientific research project of Ordos Central Hospital | Malignant tumor | | | | |
ChiCTR2000034870: A prospective, randomized controlled study of mFOLFIRINOX versus gemcitabine combined with albumin paclitaxel in the treatment of patients with unresectable pancreatic cancer |
|
|
| Recruiting | 4 | 200 | | Oxaliplatin: 85 mg/m2, intravenous infusion, day 1; leucovorin: 400 mg/m2, intravenous infusion, day 1; irinotecan: 150 mg/m2 , Intravenous infusion, day 1; bolus injection of 5-FU: 2400 mg/m2, intravenous infusion, 46 hours; once every two weeks ;Albumin paclitaxel (nab-paclitaxel): 125mg/m2, intravenous infusion (30 minutes), on day 1, 8; gemcitabine (GEM): 1000 mg/m2, intravenous infusion, on day 1, 8; Once every three weeks | Wannan Medical College; Wannan Medical College, Self-financing | Pancreatic cancer | | | | |
ChiCTR1900023924: Apatinib combined with SOX in the treatment of advanced gastric cancer: a multicenter, open randomized, controlled exploratory clinical study |
|
|
| Not yet recruiting | 4 | 116 | | apatinib combined with S-1 and oxaliplatin; S-1 and oxaliplatin | Fujian Cancer Hospital; Fujian Cancer Hospital, This study is a clinical study sponsored by the researcher. At present, it has won free oral medication sponsored by Jiangsu Hengrui Pharmaceutical Co., Ltd. (Apatinib Mesylate Tablets). | Gastric cancer | | | | |
TROJAN 021, ChiCTR1900027922: Clinical study for efficacy and safety of Oncorine (Recombinant Human Adenovirus Type 5 Injection) combined with mFOLFOX6+ bevacizumab in the treatment of unresectable colorectal adenocarcinoma with liver metastases |
|
|
| Recruiting | 4 | 210 | | Oncorine+ mFOLFOX6 + bevacizumab ;mFOLFOX6 + bevacizumab | Shanghai Tenth People's Hospital; Shanghai Tenth People's Hospital, Shanghai Science and Technology Commission/Shanghai Sunway Biotech Co., Ltd | Unresectable colorectal adenocarcinoma liver metastasis | | | | |
ChiCTR1800020419: A single-center prospective randomized controlled trial for tiggio combined with oxaliplatin (SOX) versus capecitabine combined with oxaliplatin (XELOX) in the treatment of postoperative adjuvant chemotherapy in patients with colorectal cancer |
|
|
| Not yet recruiting | 4 | 60 | | SOX ;XELOX | Yixing People's hospital; Yixing People's hospital, self-funded | colorectal cancer | | | | |
ChiCTR1900021412: A clinical study for apatinib combined with tegrio adjuvant therapy in patients with locally advanced gastric cancer after D2 radical resection |
|
|
| Recruiting | 4 | 72 | | Tegrio, twice daily, orally after breakfast and dinner, d1-14, q3w; apatinib, 250mg, po, qd, q3w ;Oxaliplatin 130 mg/m2, ivdrip，d1，q3w; tegrio, twice daily, orally after breakfast and dinner, d1-14, q3w; apatinib, 250mg, po, qd, q3w | National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Cancer Hospital Chinese Academy of Medical Sciences, None | Gastric Cancer | | | | |
ChiCTR2000030339: A multicenter, prospective, noninterventive, and registration study for raltitrexed and S-1 in the treatment of metastatic colorectal cancer with failure of fluorouracil, oxaliplatin and irinotecan |
|
|
| Recruiting | 4 | 300 | | raltitrexed with S-1 | West China Hospital, Sichuan University; West China Hospital, Sichuan University, researchers | metastatic colorectal cancer | | | | |
ChiCTR2000030610: Anti-PD-1 Antibody Carrizumab combined with FLOT versus FLOT in neoadjuvant treatment of gastric or gastroesophageal junction adenocarcinoma: a randomized, single-center and controlled trial |
|
|
| Not yet recruiting | 4 | 60 | | Carrizumab + docetaxel + oxaliplatin + calcium folinate + fluorouracil ;docetaxel + oxaliplatin + calcium folinate + fluorouracil | The Affiliated Hospital of Qingdao University; The Affiliated Hospital of Qingdao University, self-financing | gastric or gastroesophageal junction adenocarcinoma | | | | |
ChiCTR2000035291: Clinical study of SHR-1210 combined with oxaliplatin and tigio for neoadjuvant treatment of resectable gastric cancer |
|
|
| Recruiting | 4 | 60 | | SHR-1210, Oxaliplatin, Tiggio ;Oxaliplatin, Tiggio | China-Japan Friendship Hospital of Jilin University; China-Japan Friendship Hospital of Jilin University, Jiangsu Hengrui Pharmaceutical Co., Ltd. | Untreated local gastric/gastroesophageal junction adenocarcinoma | | | | |
ChiCTR2000037711: A Multicenter Prospective Clinical Trial: Conversion Therapy for RAS/BRAF Wild-Type Right-Sided Colon Cancer Patients With Initially Unresectable Liver Metastases |
|
|
| Recruiting | 4 | 520 | | FOLFOXIRI plus Cetuximab ;FOLFOXIRI plus Bevacizumab | Fudan University Zhongshan Hospital; Fudan University Zhongshan Hospital, Shanghai Shenkang Hospital Development Center; raise independently | colorectal cancer | | | | |
NCT04261920: Clinical Trial Scheme of Huangqi Guizhi Wuwu Decoction |
|
|
| Recruiting | 4 | 360 | RoW | Huangqi Guizhi Wuwu decoction, Huangqi Guizhi Wuwu decoction placebo | Jiangsu Famous Medical Technology Co., Ltd. | Oncology | 01/23 | 03/23 | | |
ChiCTR-IPR-17013680: Comparison of adjuvant chemotherapy after laparoscopic D2 radical surgery for advanced gastric cancer |
|
|
| Not yet recruiting | 4 | 180 | | Oxaliplatin 130mg / m2, intravenous infusion of the first day; capecitabine 1000mg / m2, orally, 2 times / day, 1-14 days, 21 days for a cycle. A total of 8 cycles. ;Oxaliplatin 130mg / m2, intravenous infusion of the first day; Tegafur 60mg/time, oral, two time a day in day 1 to day 14, 21 days a cycle, total 8 cycles. | Tianjin Medical University General Hospital; Tianjin Medical University General Hospital, Tianjin Medical University clinical research project | gastric cancer | | | | |
ChiCTR2100046202: Efficacy and safety of Sintilimab and oxaliplatin in combination with capecitabine or in combination with paclitaxel/albumin paclitaxel in first-line treatment of unresectable locally advanced, recurrent or metastatic gastric and gastroesophageal junction adenocarcinoma |
|
|
| Recruiting | 4 | 100 | | Immunotherapy combined with chemotherapy | Nanping First Hospital Affiliated to Fujian Medical University; Nanping First Hospital Affiliated to Fujian Medical University, Cinda Biopharmaceutical (Suzhou) Co., Ltd | gastric and gastroesophageal junction adenocarcinoma | | | | |
ChiCTR2100049944: Tislelizumab plus Gemox in relapsed or refractory patients with ENKTCL |
|
|
| Not yet recruiting | 4 | 30 | China | Tislelizumab in combination with gemcitabine and oxaliplatin | Jiangsu Provincial People's Hospital ; Jiangsu Provincial People's Hospital, Self-collected | ENKTCL | | | | |
ChiCTR2100049305: Space-neo study: a single arm study of apatinib combined with carrelizumab and SOX regimen in neoadjuvant treatment of local advanced gastric/gastroesophageal junction adenocarcinoma |
|
|
| Recruiting | 4 | 32 | | Apatinib + Carrelizumab + Oxaliplatin + Tegafur, three-week course | Jiangsu Province Hospital; Jiangsu Province Hospital, None | Locally advanced adenocarcinoma of the gastroesophageal junction | | | | |
NCT05510856: Comparative Clinical Study Evaluating the Possible Efficacy of Duloxetine, Gabapentin and Lacosamide on Oxaliplatin-Induced Peripheral Neuropathy in Cancer Patients |
|
|
| Recruiting | 4 | 90 | RoW | Duloxetine, Gabapentin, Lacosamide | Tanta University | Oncology | 09/23 | 09/24 | | |
| Recruiting | 4 | 60 | RoW | Venlafaxine 75 MG, Gabapentin 400 mg | Mit Ghamr Oncology Center | Peripheral Neuropathy Due to Chemotherapy | 10/23 | 12/23 | | |
NCT04747951: Total Neoadjuvant Therapy in Rectal Cancer Treatment |
|
|
| Recruiting | 4 | 280 | RoW | Concurrent Chemoradiotherapy, Radiotherapy, TME, consolidation chemotherapy, XELOX, CAPOX, adjuvant chemotherapy, mFOLFOX | State Scientific Centre of Coloproctology, Russian Federation | Rectal Cancer | 10/23 | 11/23 | | |
ChiCTR2000032702: Efficacy and safety of Paclitaxel (Albumin-bound) combined with Oxaliplatin and S-1 in preoperative adjuvant treatment of gastric cancer |
|
|
| Recruiting | 4 | 70 | | Paclitaxel(Albumin-bound) | Gansu Provincial Hospital; Gansu Provincial Hospital, Self-raising | Gastric cancer | | | | |
NCT06192186: Adebrelimab Combined With SOX Regimen in Preoperative Neoadjuvant Transformation Therapy for Locally Advanced Gastric Adenocarcinoma |
|
|
| Recruiting | 4 | 110 | RoW | Adebrelimab combined with SOX regimen, Placebo combined with SOX (S-1/oxaliplatin) regimen | Yang Jianjun, PhD | Locally Advanced Gastric Adenocarcinoma | 12/25 | 12/25 | | |
ChiCTR2100042385: A prospective, non-randomized, multi-cohort study of apatinib mesylate combined with XeLox-based protocol for perioperative treatment of resectable gastric cancer |
|
|
| Recruiting | 4 | 101 | | Apatinib mesylate + carririzumab + capetabine + oxaliplatin ;Apatinib mesylate + capetabine + oxaliplatin | Tangdu Hospital of Air Force Medical University; Tangdu Hospital of Air Force Military Medical University, self-raised | Cancer of the stomach | | | | |
| Not yet recruiting | 4 | 60 | | Dexamethasone + tofacitinib ;Tofacitinib + etoposide + dexamethasone ;High-dose decitabine ;gemcitabine + mitoxantrone + oxaliplatin + dexamethasone | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Top Young Talents Program of Hubei Province 2021 | hemophagocytic lymphohistiocytosis | | | | |
NCT02366819: Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer |
|
|
| Recruiting | 4 | 36 | US | Oxaliplatin, Leucovorin Calcium, CF, Irinotecan Hydrochloride, Fluorouracil, Conventional Surgery, surgery, conventional | University of Chicago, National Cancer Institute (NCI) | Esophageal Adenocarcinoma, Gastric Adenocarcinoma, Stage IIB Gastric Cancer, Stage IIIA Esophageal Adenocarcinoma, Stage IIIA Gastric Cancer, Stage IIIB Esophageal Adenocarcinoma, Stage IIIB Gastric Cancer, Stage IIIC Esophageal Adenocarcinoma, Stage IIIC Gastric Cancer | 06/25 | 06/25 | | |
NCT05124002: Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 4 | 66 | RoW | Recombinant Human Adenovirus Type 5, H101, HAIC of FOLFOX, FOLFOX | Beijing Tsinghua Chang Gung Hospital | Cholangiocarcinoma, Intrahepatic | 04/26 | 04/26 | | |
NCT06311942: Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC. |
|
|
| Recruiting | 4 | 300 | RoW | HAIC plus PD-1 inhibitors plus lenvatinib, Non, PD-1 inhibitors plus lenvatinib | Chen Xiaoping | HCC | 12/27 | 12/28 | | |
ChiCTR2100045251: Surufatinib plus gemcitabine and oxaliplatin (GEMOX) in patients with unresectable or metastatic biliary tract cancer (BTC): a single-arm, open-label, multi-center trial |
|
|
| Recruiting | 4 | 42 | | Sofantinib combined with gemcitabine, oxaliplatin | The First Affiliated Hospital of Sun Yat-Sen University; The First Affiliated Hospital of Sun Yat-Sen University, Company | biliary tract cancers | | | | |
NCT06311916: Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model. |
|
|
| Not yet recruiting | 4 | 312 | NA | HAIC + Tirelizumab +lenvatinib +liver resection, Non, liver resection | Chen Xiaoping | HCC | 12/27 | 12/28 | | |
NCT06368063: The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer |
|
|
| Recruiting | 4 | 642 | RoW | Huaier granule, Z20000109#NMPA Approval Number#, chemotherapy drugs, Standard chemotherapy | Health Science Center of Xi'an Jiaotong University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology | Pancreatic Cancer Resectable | 03/26 | 03/28 | | |
NCT06417606: Lenvatinib and Adebrelimab Combined With GEMOX in the Perioperative Treatment of Potentially Resectable Intrahepatic Cholangiocarcinoma |
|
|
| Not yet recruiting | 4 | 20 | RoW | Lenvatinib, Adebrelimab, GEMOX（Gemcitabine and oxaliplatin） | Zhiyong Huang | Intrahepatic Cholangiocarcinoma | 04/25 | 05/25 | | |
ChiCTR2000030887: The efficacy and safety of triple-drug regimen of docetaxel, oxaliplatin combing with capecitabine and two-drug regimen of oxaliplatin combing with capecitabine in the treatment of adenocarcinoma at the junction of stomach and gastroesophageal in IIIB and IIIc stage: a randomized controlled phase III clinical study |
|
|
| Not yet recruiting | 4 | 196 | | docetaxel plus oxaliplatin and capecitabine ;oxaliplatin plus capecitabine | He'nan Cancer Hospital; Henan Cancer Hospital, self-raised | Gastric carcinoma | | | | |
ChiCTR2300068184: Camrelizumab combined with chemotherapy in neoadjuvant treatment of gastroesophageal junction cancer: A single-arm, single-center, exploratory clinical study |
|
|
| Recruiting | 4 | 87 | | Camrelizumab 200mg, d1; Albumin paclitaxel 100mg/m^2, d1; S-1 60mg/m^2, bid, d1-14; Oxaliplatin 130mg/m^2, d1, q3w, 2-4 cycles in total. | Affiliated Cancer Hospital of Shandong First Medical University; Affiliated Cancer Hospital of Shandong First Medical University, Self-funded | Gastroesophageal junction carcinoma | | | | |
ChiCTR1900026291: Anlotinib Combined with SOX Regimen (S1 [Tegafur, Gimeracil and Oteracil Porassium Capsules] + oxaliplatin) in Treating Stage IV Gastric Cancer: A Single-Armed and Single Center Clinical Trial |
|
|
| Not yet recruiting | 4 | 150 | | Anlotinib Combined with SOX Regimen | Gang Ji; Xijing Hospital, The Fourth Military Medical University, National Natural Science Foundation of China (81502401 and 31670828) | Gastric Cancer | | | | |
ChiCTR2200065729: Phase II clinical study of PD-1 combined with SOX in perioperative treatment of resectable adenocarcinoma of stomach and gastroesophageal junctionPhase II clinical study of PD-1 combined with SOX in perioperative treatment of resectable adenocarcinoma of stomach and gastroesophageal junction |
|
|
| Not yet recruiting | 4 | 50 | | camrelizumab+ Oxaliplatin + Tegafur | Jiaozuo No.2 People's Hospital; Jiaozuo No.2 People's Hospital, self-supporting | Gastric adenocarcinoma | | | | |
CRC - PTX, NCT06115174: Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer |
|
|
| Not yet recruiting | 4 | 44 | NA | Pentoxifylline, FOLFOX, XELOX, Monoclonal antibodies (target therapy) | Tanta University | Metastatic Colorectal Carcinoma | 11/24 | 12/24 | | |
ChiCTR2300074767: Open-label, single-arm, single-center Phase Ib/ II clinical study of fruquintinib combined with trastuzumab and XELOX in the first-line treatment of advanced HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma |
|
|
| Recruiting | 4 | 51 | | fruquintinib combined with trastuzumab and XELOX | Henan Cancer Hospital; Henan Cancer Hospital, CSCO Fund | Adenocarcinoma of the stomach or gastroesophageal junction | | | | |
ChiCTR2100044005: A phase II clinical study of SOXIRI for advanced first-line treatment of unresectable, recurrence and metastasis pancreatic cancer |
|
|
| Recruiting | 4 | 33 | | S-1 60mg/m2 + oxaliplatin 85mg/m2 + irinotecan 150mg/m2 | Shandong Cancer Hospital; Shandong Cancer Hospital, NA | pancreatic cancer | | | | |
NCT06090994: Prevention of Postoperative Recurrence and Metastasis of Colorectal Cancer by Comparing Huaier With Standard Treatment |
|
|
| Not yet recruiting | 4 | 648 | RoW | Huaier granule, Z20000109（NMPA Approval Number） | Fudan University | Colorectal Cancer | 09/27 | 09/28 | | |
NCT05498766: Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients |
|
|
| Not yet recruiting | 4 | 702 | RoW | Huaier granule, Z20000109, Oxaliplatin, Tegafur, Gimeracil and Oteracil Potassium | Wuhan Union Hospital, China, LinkDoc Technology (Beijing) Co. Ltd. | Gastric Cancer | 07/29 | 11/29 | | |
| Not yet recruiting | 3 | 100 | | | Epworth HealthCare, Epworth HealthCare | Pancreatic cancer | | | | |
SHR-A1811-309, CTR20234257: A randomized, open-label, active-controlled, multicenter phase III clinical study of SHR-A1811 for injection versus investigator-selected treatment regimen in patients with advanced colorectal cancer who have failed treatment with oxaliplatin, fluorouraci |
|
|
| Ongoing | 3 | 120 | China | trastuzumab rezetecan (SHR-A1811) - Jiangsu Hengrui Pharma, Lonsurf (trifluridine/tipiracil) - Servier, Otsuka, Stivarga (regorafenib) - Bayer, Fruzaqla (fruquintinib) - Takeda | Shanghai Hengrui Pharmaceutical Co., Ltd./ Jiangsu Hengrui Pharmaceutical Co., Ltd./ Suzhou Shengdia Biopharmaceutical Co., Ltd | Colorectal cancer | | | | |
ChiCTR-TRC-12002734: S-1 plus oxaliplatin (SOX) versus fluorouracil and folinic acid plus oxaliplatin (mFOLFOX6) for first-line treatment of patients with metastatic colorectal cancer: a randomised controlled trial |
|
|
| Completed | 3 | 360 | | S-1 plus oxaliplatin ;fluorouracil and folinic acid plus oxaliplatin | West China Hospital, Sichuan University; Shandong New Time（age） Pharmaceutical Co., LTD, Shandong New Time (age) Pharmaceutical Co., LTD | Shandong New Time (age) Pharmaceutical Co., LTD | | | | |
2007-007059-14: Role of the Glutatione reduced in the prevention of neuro-toxicity from Oxaliplatino. Ruolo del Glutatione ridotto nella prevenzione della neurotossicita' da Oxaliplatino. |
|
|
| Ongoing | 3 | 180 | Europe | Powder and solvent for solution for infusion | AZIENDA DI RILIEVO NAZIONALE E DI ALTA SPECIALIZZAZIONE OSPEDALE CIVICO E BENFRATELLI, G.DI CRISTINA E M.ASCOLI | Patients with neoplasia malignant. Pazienti con neoplasia maligna. | | | | |
NCT00705029: Alpha-Lipoic Acid in Preventing Peripheral Neuropathy in Patients Receiving Chemotherapy for Cancer |
|
|
| Recruiting | 3 | 244 | US | alpha-lipoic acid, placebo | University of Medicine and Dentistry New Jersey, M.D. Anderson Cancer Center, Jarrow Formulas Inc | Neurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific | 01/09 | | | |
2008-000837-23: mEOC: Chemotherapy in chemonaïve patients with mucinous ovarian cancer |
|
|
| Ongoing | 3 | 336 | Europe | Carboplatin, Paclitaxel, Oxaliplatin, Capecitabine, , Solution for infusion, Concentrate for solution for infusion, Tablet, Avastin | University College London, POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI, , Roche | Mucinous ovarian cancer, stages II-IV and stage I recurrent, MUCINOUS OVARIAN CANCER CARCINOMA MUCINOSO OVAIO, Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | | | | |
ChiCTR-TRC-08000061: Randomized controlled trial on the treatment of advanced gastric cancer by POF and IF regimes |
|
|
| Recruiting | 3 | 200 | | Irinotecan 80 mg/m2 ivgtt. for 30 minutes, formyltetrahydrofolate 500 mg/m2 ivgtt. for 2 hours; and then use fluorouracil 2000 mg/m2 ivgtt. for 22 hours. The treatment is given once a week for 6 weeks and repeated after a week's interval. ;Taxol 135 mg/m2 ivgtt. for 3 hours; then use formyltetrahydrofolate 400 mg/m2 ivgtt. for 2 hours and oxaliplatin 85 mg/m2 ivgtt. for 2 hours; and then use fluorouracil 2400 mg/m2 ivgtt. for 46 hours. One treatment cycle lasts 14 days. | Fujian Provincial Tumor Hospital; Fujian Anti-cancer Association, Fujian Anti-cancer Association | Gastric Cancer | | | | |
2011-004406-25: Etude randomisée de phase III comparant une radiochimiothérapie préopératoire à une chimiothérapie néoadjuvante Folfirinox suivie de radiochimiothérapie préopératoire pour les patients atteints de cancers du rectum localement avancés (étude PRODIGE-GERCOR-SFRO-GRECCAR) |
|
|
| Not yet recruiting | 3 | 460 | Europe | OXALIPLATINE, IRINOTECAN, ACIDE FOLINIQUE, 5-FLUOROURACILE, Solution for injection/concentrate for solution for infusion, Powder and solution for solution for injection, ELOXATINE, CAMPTO, ELVORINE, 5-FLUOROURACIL | UNICANCER, PHRC | Adénocarcinome du rectum, Cancer du rectum, Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 3 | 263 | Europe, US | bleomycin sulfate, cisplatin, etoposide, ifosfamide, oxaliplatin, paclitaxel | UNICANCER | Extragonadal Germ Cell Tumor, Teratoma, Testicular Germ Cell Tumor | 03/12 | 12/24 | | |
2011-005003-32: A study comparing the effect of chemotherapy with the effect of chemotherapy plus local removal of metastases for patients with cancer of the large bowel which has spread to multiple organs. |
|
|
| Ongoing | 3 | 478 | Europe | capecitabin, oxaliplatin, bevacizumab, fluorouracil, Folinic acid, Film-coated tablet, Concentrate for solution for infusion, Concentrate for solution for injection/infusion, Solution for injection/infusion, Xeloda, Eloxatin, Avastin, Fluorouracil, Sodiofolin | VU University Medical Center, Department of Medical Oncology, VU University Medical Center, Department of Medical Oncology | multi-organ metastatic colorectal cancer, Patients with metastases of large bowel cancer in multiple organs, Diseases [C] - Cancer [C04] | | | | |
LOGiC, NCT00680901 / 2007-005725-29: - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib |
|
|
| Active, not recruiting | 3 | 545 | Europe, Canada, US, RoW | Lapatinib, Tykerb, Tyverb, Placebo, Capecitabine, Oxaliplatin | Novartis Pharmaceuticals | Neoplasms, Gastrointestinal Tract | 09/12 | 01/25 | | |
|
|
|
2012-005748-12: D2 Resection and HIPEC (Hyperthermic intraperitoneal chemoperfusion) in locally advanced gastric carcinoma. A national randomized and multicentric phase III study INTERET DE LA CHIMIOHYPERTHERMIE INTRAPERITONEALE (CHIP) ADJUVANTE A L’OXALIPLATINE DANS LE TRAITEMENT CURATIF DES CANCERS GASTRIQUES AVANCES. ETUDE NATIONALE, RANDOMISEE ET MULTICENTRIQUE DE PHASE III. |
|
|
| Ongoing | 3 | 322 | Europe | 5 Fluorouracilo, L01B1A, Solution for injection/infusion, Oxaliplatin, 5 Fluorouracilo, Levofolinate Calcium | Hospices Civils de Lyon, Ministère de la Santé, Hospices Civils de Lyon | Gastric adenocarcinoma, Stomach cancer, Diseases [C] - Digestive System Diseases [C06] | | | | |
2013-003244-23: Study evaluating, as first-line treatment of metastatic colorectal cancer, Bevacizumab +FOLFIRI followed by Bevacizumab + FOLFOX( or XELOX) or the reverse sequence Bevacizumab + FOLFOX (or XELOX) folloewed by Bevacizumab + FOLFIRI versus the standard Bevacizumab+ FOLFIRI Studio che mette a confronto, come trattamento di prima linea del tumore metastatico del colon-retto, il Bevacizumab + FOLFIRI seguito da Bevacizumab + FOLFOX (o XELOX) oppure la squenza inversa Bevacizumab + FOLFOX ( o XELOX) seguito da Bevacizumab + FOLFIRI contro la terapia standard che prevde Bevacizumab + FOLFIRI. |
|
|
| Ongoing | 3 | 400 | Europe | Concentrate for solution for infusion, Film-coated tablet, Solution for infusion, Powder for infusion, Avastin, CAMPTO, OXALIPLATINO, XELODA, FLUOROURACILE TEVA, LEVOFOLENE | S.I.C.O.G. ONLUS, S.I.C.O.G. ONLUS | Unresectable and metastatic colorectal cancer carcinoma del colon-retto inoperabile e metastatico, Advanced tumour of colon/rectum Tumore avanzato del colon-retto, Diseases [C] - Cancer [C04] | | | | |
ChiCTR-TRC-12002121: Preventive use of lamivudine in postgastrectomy adenocarcinoma patients carrying HBV to prevent from severe liver damage and viral activation |
|
|
| Completed | 3 | 60 | | lamivudine ;Radiotherapy combined with Chemotherapy that contains oxaliplatin | West China Hospital, Sichuan University; Level of the institution：, Hospital funding | gastric cancer and HBV | | | | |
2014-004436-19: Phase III study to compare two different chemotherapy treatments to determine whether the first line with the three drugs + bevacizumab followed by a second line with the same regimen may provide better results than treatment with two drugs + bevacizumab is the first and the second treatment line Studio di fase III per confrontare due diversi trattamenti chemioterapici per valutare se la prima linea con tre farmaci + bevacizumab seguita da una seconda linea con lo stesso schema terapeutico possa fornire risultati migliori rispetto a un trattamento con due farmaci + bevacizumab sia nella prima che nella seconda linea di trattamento |
|
|
| Ongoing | 3 | 654 | Europe | Bevacizumab, 5 Fluorouracile, Irinotecan, Oxaliplatino, acido levo-folinico (L-Leucovorin), Bevacizumab, 5 Fluorouracile, Irinotecan, Oxaliplatino, acido levo-folinico (L-Leucovorin), Concentrate for solution for infusion, Solution for infusion, Powder for solution for infusion, Avastin, FLUOROURACILE TEVA* 500mg/10 ml, IRINOTECAN TEVA* 20 mg/ml, OXALIPLATINO TEVA* 5 mg/ml, LEDERFOLIN PFIZER* 25 mg | G.O.N.O., Roche S.p.A. | METASTATIC COLORECTAL CANCER Carcinoma colorettale metastatico (mCRC), metastatic tumor of colon-rectum, Diseases [C] - Cancer [C04] | | | | |
NCT01081262: Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer |
|
|
| Active, not recruiting | 3 | 50 | US | Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, CT-P16, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Capecitabine, Ro 09-1978/000, Xeloda, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Laboratory Biomarker Analysis, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Quality-of-Life Assessment, Quality of Life Assessment | National Cancer Institute (NCI), NRG Oncology | Borderline Ovarian Mucinous Tumor, Ovarian Mucinous Cystadenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Stage IA Fallopian Tube Cancer AJCC v6 and v7, Stage IA Ovarian Cancer AJCC v6 and v7, Stage IB Fallopian Tube Cancer AJCC v6 and v7, Stage IB Ovarian Cancer AJCC v6 and v7, Stage IC Fallopian Tube Cancer AJCC v6 and v7, Stage IC Ovarian Cancer AJCC v6 and v7, Stage IIA Fallopian Tube Cancer AJCC v6 and v7, Stage IIA Ovarian Cancer AJCC V6 and v7, Stage IIB Fallopian Tube Cancer AJCC v6 and v7, Stage IIB Ovarian Cancer AJCC v6 and v7, Stage IIC Fallopian Tube Cancer AJCC v6 and v7, Stage IIC Ovarian Cancer AJCC v6 and v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7 | 02/15 | 03/25 | | |
|
2013-003047-29: BALLAD UK- a trial to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma |
|
|
| Ongoing | 3 | 120 | Europe | Fluorouracil, Folinic Acid, Capecitabine, Oxaliplatin, Solution for injection/infusion, Film-coated tablet, Solution for infusion | Greater Glasgow and Clyde Health Board, University of Glasgow, CRUK | Small Bowel Adenocarcinoma, Small Bowel Adenocarcinoma, Diseases [C] - Cancer [C04] | | | | |
ChiCTR-TRC-12002919: A randomized phase III trial of concurrent chemoradiotherapy consisting of S-1 and oxaliplatin (SOX) in gastric cancer with radical D2 lymph node dissection |
|
|
| Recruiting | 3 | 620 | | concurrent chemoradiotherapy ;chemoradiotherapy | Department of medical oncology, Cancer Center, West China Hospital, Sichuan University; West China Hospital, Sichuan University, Self financed | gastric cancer | | | | |
2011-001858-28: A clinical trial for people who have cancer of the food pipe and junction of the food pipe and stomach, to compare chemotherapy before and after surgery, with chemotherapy with radiotherapy before surgery. |
|
|
| Ongoing | 3 | 378 | Europe | Epirubicin, Cisplatin, 5 Fluorouracil, Capecitabine, Paclitaxel, Carboplatin, Oxaliplatin, Carboplatin, Cisplatin, Epirubicin, Capecitabine, Fluorouracil, Paclitaxel, Eloxatin, Carboplatin, Cisplatin, Epirubicin, Capecitabine, Fluorouracil, Paclitaxel, Eloxatin | ICORG, ICORG- All Ireland Cooperative Oncology Research Group, ICORG, | Adenocarcinoma of the oesophagus and oesophago-gastric junction | | | | |
2013-004952-39: Chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases The CHARISMA randomized multicenter clinical trial Chemotherapie gevolgd door chirurgie versus chirurgie alleen in hoog-risico patienten met resectabele colorectale levermetastasen De CHARISMA gerandomiseerde multicenter trial |
|
|
| Ongoing | 3 | 224 | Europe | Oxaliplatin, Xeloda/Capecitabine, Oxaliplatin, Xeloda / Capecitabine, Oxaliplatin, Xeloda / Capecitabine | Erasmus MC Cancer Institute, KWF Kankerfonds | Colorectal liver metastases Colorectale levermetastasen | | | | |
| Recruiting | 3 | 300 | | Maintain with capecitabine after XELOX or FOLFOX treatment ;XELOX or FOLFOX | West China Hospital，Sichuan University; West China Hospital，Sichuan University, No-funds | advanced colorectal cancer | | | | |
2016-002331-16: Comparaison d'un traitement par FOLFOX (Oxaliplatine et 5 FU) et du traitement par TFOX (oxaliplatine + 5 FU et Docetaxel) chez les patients ayant un cancer de l'estomac ou de la jonction entre estomac et oesophage localement avancé ou métastatique |
|
|
| Not yet recruiting | 3 | 506 | Europe | Solution for infusion, TAXOTERE | Fédération Francophone de Cancérologie Digestive, Fédération Francophone de Cancérologie Digestive | Cancer de l'estomac et de la jonction oeso-gastrique localement avancé ou métastatique, Patient présentant un cancer de l'estomac ou de la jonction estomac-oesophage localement avancé ou avec des métastases, Diseases [C] - Cancer [C04] | | | | |
ChiCTR-TRC-13003139: Paclitaxel plus S-1 (TS) versus oxaliplatin and S-1(SOX) for treatment of advanced diffuse-type gastric cancer: a multicenter, randomised ,controlled trial |
|
|
| Recruiting | 3 | 238 | | Paclitaxel plus S-1 ;Oxaliplatin plus S-1 | West China Hospital; Level of the institution：, self-funded | advanced diffuse-type gastric cancer | | | | |
2016-004394-40: FOLFOXIRI plus Panitumumab or FOLFOX plus Panitumumab in the treatment of metastatic colorectal cancer. folfoxiri più panitumumab contro folfox più panitumumab nel carcinoma del colonretto metastatico. |
|
|
| Ongoing | 3 | 432 | Europe | Panitumumab, Fluorouracile, Oxaliplatino, Calcio Levofolinato, Irinotecan, [Panitumumab], [Fluorouracile], [Oxaliplatino], [Calcio Levofolinato], [Irinotecan], Solution for infusion, VECTIBIX - 20 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO 1 FLACONCINO (VETRO) 20 ML, FLUOROURACILE AHCL - 50MG/ML SOLUZIONE INIETTABILE O INFUSIONE 1 FLACONCINO IN VETRO DA 100 ML, OXALIPLATINO ACCORD - 5 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 40 ML, CALCIO LEVOFOLINATO TEVA - 25 MG POLVERE PER SOLUZIONE INIETTABILE 1 FLACONCINO, IRINOTECAN CSC - 20 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 15 ML | Fondazione GONO, Amgen, G.O.N.O. | Metastatic Colorectal Cancer Carcinoma Colorettale metastatico, colorectal cancer spread at distance tumore al colon retto diffuso a distanza, Diseases [C] - Cancer [C04] | | | | |
ChiCTR-TRC-11001560: A multi-center clinical trail for Tegafur, gimeracil and oteracil potassium capsules combined with Oxaliplatin in treatment of phase II, IIIa gastric cancer |
|
|
| Recruiting | 3 | 240 | | Tegafur, Gimeracil and Oteracil Potassium Capsules 40 mg/m2, B.i.d P.O.; Oxaliplatin 130 mg/m2, d1-14, integrated in 5% GS 250 ml, ivgtt 120/min; repeated every 3 weeks ;Tegafur, Gimeracil and Oteracil Potassium Capsules 40 mg/m2, B.i.d ,P.O., d1-14; repeated evey 3 weeks | Henan Cancer Hospital; iang Shu Heng Rui Medicine Company Limited By Shares. No. 7, Kunlun mountain Road, Lianyungang Economic and Technological Development Zone, Jiangshu, China, Jiang Shu Heng Rui Medicine Company Limited By Shares | gastric cancer | | | | |
2016-002272-27: Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to a standard chemotherapy. |
|
|
| Ongoing | 3 | 388 | Europe | Opdivo, Solution for injection, Opdivo | Saarland University, Bristol-Myers Squibb | Patients with first relapse or progression of aggressive Non-Hodgkin’s Lymphoma who are not eligible neither for autologous nor allogeneic stem cell transplantation, Patients with first relapse or progression of aggressive Non-Hodgkin’s Lymphoma who are not eligible neither for autologous nor allogeneic stem cell transplantation, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
2017-002036-17: The (cost)effectiveness of preoperative chemotherapy versus preoperative gemcitabine based chemoradiotherapy and adjuvant gemcitabine in patients with pancreatic cancer. |
|
|
| Ongoing | 3 | 368 | Europe | Leucovorin calcium, Fluorouracil, Irinotecan, Oxaliplatin, Powder for solution for injection/infusion, Solution for infusion, Concentrate for solution for infusion, LEUCOVORIN CALCIUM, Fluorouracil, Irinotecan, Oxaliplatin | Erasmus Medical Center, ZonMw, KWF | (borderline) resectable pancreatic cancer, (possible) resectable pancreatic cancer, Diseases [C] - Cancer [C04] | | | | |
2018-000377-68: Treatment for Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas |
|
|
| Ongoing | 3 | 218 | Europe | Paclitaxel in cationic liposomes, EndoTAG-1, Powder and solvent for concentrate for solution for infusion | SynCore Biotechnology Co., Ltd., SynCore Biotechnology Co., Ltd. | Unresectable Locally Advanced/ Metastatic Adenocarcinoma of the Pancreas, Unresectable Locally Advanced/ Metastatic Adenocarcinoma of the Pancreas, Diseases [C] - Cancer [C04] | | | | |
2014-002517-39: Randomised phase III trial evaluating adjuvant chemotherapy after the stage III colon adenocarcinoma resection for patient of 70 year old or more ETUDE DE PHASE III RANDOMISEE EVALUANT LA CHIMIOTHERAPIE ADJUVANTE APRES RESECTION D’UN ADENOCARCINOME COLIQUE DE STADE III CHEZ LES PATIENTS DE 70 ANS ET PLUS |
|
|
| Ongoing | 3 | 982 | Europe | Solution for infusion, Film-coated tablet, Fluorouracil Accord Healthcare 50 mg/ml, solution pour injection ou perfusion, Elvorine 25 mg/2,5 ml solution injectable Elvorine 50 mg/5 ml solution injectable, Xeloda 150 mg comprimés pelliculés. Xeloda 500 mg comprimés pelliculés., ELOXATIN 5 mg/ml solution à diluer pour perfusion | Fédération Francophone de Cancérologie Digestive (FFCD), FFCD itself, Belgian Group Digestive Oncology( BGDO) | Adjuvant treatment in stage III adenocarcinoma of the colon fully resected for patient of 70 years and over Traitement adjuvant d'un adénocarcinome colique de stade III totalement réséqué chez les patients de 70 ans et plus, Adjuvant treatment in stage III adenocarcinoma of the colon fully resected for patient of 70 years and over Traitement adjuvant d'un adénocarcinome colique de stade III totalement réséqué chez les patients de 70 ans et plus, Diseases [C] - Cancer [C04] | | | | |
2018-002886-21: A Phase III randomized study evaluating gemcitabine and paclitaxel versus gemcitabine alone after FOLFIRINOX failure or intolerance in Metastatic Pancreatic Ductal Adenocarcinoma. |
|
|
| Not yet recruiting | 3 | 210 | Europe | Powder for concentrate for solution for infusion, Concentrate for solution for infusion | UNICANCER, Programme hospitalier de recherche clinique (PHRC) | Metastatic Pancreatic Ductal Adenocarcinoma, Advanced pancreas cancer, Diseases [C] - Cancer [C04] | | | | |
2018-002831-65: BALLAD BELGIUM: A trial to evaluate the potential benefit of adjuvant chemotherapy, that means a chemotherapy in addition to the curative surgery for small bowel adenocarcinoma |
|
|
| Ongoing | 3 | 30 | Europe | Solution for infusion, Film-coated tablet, Fluorouracil Accord Healthcare 50 mg/ml, solution pour injection ou perfusion, Elvorine 25 mg/2,5 ml solution injectable Elvorine 50 mg/5 ml solution injectable, Xeloda 150 mg comprimés pelliculés, Xeloda 500 mg comprimés pelliculés, ELOXATIN 5 mg/ml solution à diluer pour perfusion | Belgian Group of Digestive Oncology (BGDO), Belgian Group of Digestive Oncology (BGDO) | small bowel adenocarcinoma, SMALL BOWEL ADENOCARCINOMA, Diseases [C] - Cancer [C04] | | | | |
PRODIGY, NCT01515748: Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer |
|
|
| Completed | 3 | 530 | RoW | Docetaxel (XRP6976), Oxaliplatin (SR96669), S-1 (1-(2-tetrahydrofuryl)-5-fluorouracil + 5-chloro-2, 4-dihydroxypyridine (CDHP) (Gimeracil) + Oxo (Oteracil) | Sanofi | Gastric Cancer | 01/19 | 12/21 | | |